![James Brady](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
James Brady
Direktor/Vorstandsmitglied bei
XERIS BIOPHARMA HOLDINGS, INC.
Vermögen: 698 291 $ am 31.05.2026
Profil
James Brady is an Independent Non-Executive Director at Xeris Biopharma Holdings, Inc. since 2025.
Former roles include Director at Panavance Therapeutics, Inc. from 2021 to 2025, Independent Non-Executive Director at Verona Pharma Ltd. from 2022 to 2025, Chief Financial Officer at MedImmune Ltd. from 2013 to 2018, and Chief Audit Executive at AstraZeneca PLC from 2009 to 2012.
Education includes an MBA from Drexel University and an undergraduate degree from St. Joseph University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 04.06.2026 | 113’359 ( 0.07% ) | 698 291 $ | 31.05.2026 |
Aktive Positionen von James Brady
| Unternehmen | Position | Beginn |
|---|---|---|
| XERIS BIOPHARMA HOLDINGS, INC. | Direktor/Vorstandsmitglied | 28.03.2025 |
Ehemalige bekannte Positionen von James Brady
| Unternehmen | Position | Ende |
|---|---|---|
| VERONA PHARMA PLC | Direktor/Vorstandsmitglied | 07.10.2025 |
Panavance Therapeutics, Inc.
 Panavance Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Direktor/Vorstandsmitglied | 01.02.2025 |
MedImmune Ltd.
 MedImmune Ltd. BiotechnologyHealth Technology Engages in research and development of human monoclonal antibodies | Finanzdirektor/CFO | 01.01.2018 |
| ASTRAZENECA PLC | Comptroller/Controller/Auditor | 01.01.2012 |
Ausbildung von James Brady
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
77
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
MedImmune Ltd.
MedImmune Ltd. BiotechnologyHealth Technology Engages in research and development of human monoclonal antibodies | Health Technology |
Drexel University
 Drexel University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Verona Pharma Plc
 Verona Pharma Plc Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of allergic rhinitis and other chronic respiratory diseases | Health Technology |
St. Joseph University
 St. Joseph University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Xeris Biopharma Holdings, Inc.
 Xeris Biopharma Holdings, Inc. BiotechnologyHealth Technology Develops and commercializes therapies | Health Technology |
Panavance Therapeutics, Inc.
Panavance Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Health Technology |
